Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Insight in the prediction of chemotherapy-induced nausea.

Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L, Hoelzer K, Jacobs A.

Support Care Cancer. 2010 Jul;18(7):869-76. doi: 10.1007/s00520-009-0723-2. Epub 2009 Aug 23.

2.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
4.

Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.

Shih V, Wan HS, Chan A.

Ann Pharmacother. 2009 Mar;43(3):444-52. doi: 10.1345/aph.1L437. Epub 2009 Feb 3.

PMID:
19193584
5.

Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.

Iwasaki K, Obara W, Kato Y, Takata R, Tanji S, Fujioka T.

Jpn J Clin Oncol. 2013 Feb;43(2):193-9. doi: 10.1093/jjco/hys213. Epub 2012 Dec 28.

6.
7.

Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.

Feinberg B, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D.

Support Care Cancer. 2012 Mar;20(3):615-23. doi: 10.1007/s00520-011-1140-x. Epub 2011 Mar 29.

PMID:
21761096
9.
10.

Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.

Markman MR, Peterson G, Kulp B, Markman M.

Gynecol Oncol. 2002 Jun;85(3):435-7.

PMID:
12051870
12.

A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.

Sorbe BG, Berglind AM, Andersson H, Boman K, Högberg T, Hallgren M, Schmidt M.

Cancer. 1998 Sep 1;83(5):1022-32.

PMID:
9731907
13.
14.

Comparison of antiemetic efficacy between single and repeat treatment with dexamethasone in patients receiving carboplatin-based combination chemotherapy.

Kawazoe H, Motoki Y, Takechi Y, Shishino Y, Ido K, Suemaru K, Araki H.

Methods Find Exp Clin Pharmacol. 2010 Sep;32(7):499-505. doi: 10.1358/mf.2010.32.7.1501438.

PMID:
21069101
15.

ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.

Harper P.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-23-S15-25.

PMID:
9346217
17.
19.

Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.

Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.

J Med Assoc Thai. 2006 Oct;89 Suppl 4:S29-36.

PMID:
17725140
20.

Lorazepam: a randomized, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine.

Bishop JF, Olver IN, Wolf MM, Matthews JP, Long M, Bingham J, Hillcoat BL, Cooper IA.

J Clin Oncol. 1984 Jun;2(6):691-5.

PMID:
6374058
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk